Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD F TUTRONE

Allopathic & Osteopathic Physicians Urology

NPI
1265495204
CMS profile
284752
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,792.15

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD F TUTRONE

NPI 1265495204 · CMS profile ID 284752

Allopathic & Osteopathic Physicians / Urology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $1,792.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ferring Pharmaceuticals Inc. $20.6402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137515952 CMS
Janssen Biotech, Inc. $72.0102/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078710040 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.9702/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086192492 CMS
Dendreon Pharmaceuticals LLC $10.6301/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149325200 CMS
PROGENICS PHARMACEUTICALS, INC. $113.1901/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128515033 CMS
PROGENICS PHARMACEUTICALS, INC. $19.5501/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128513663 CMS
PFIZER INC. $13.0901/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131107183 CMS
Dendreon Pharmaceuticals LLC $16.0901/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149325198 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,418.71 73
PY2020 $14,083.47 20
PY2021 $9,899.67 36
PY2022 $23,237.30 54
PY2023 $23,866.07 69
PY2024 $1,792.15 58
PY2025 $2,438.72 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,891.99 11
PY2025 Principal investigator $4,225,291.52 215
PY2024 Recipient $7,737.86 5
PY2024 Principal investigator $2,849,872.01 168
PY2023 Recipient $19,163.31 19
PY2023 Principal investigator $2,270,234.16 206
PY2022 Recipient $1,316.00 1
PY2022 Principal investigator $2,576,328.25 318
PY2021 Principal investigator $1,359,876.91 251
PY2020 Principal investigator $2,848,670.78 347
PY2019 Principal investigator $1,914,676.85 329

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

226 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $21,041.48 12/31/2025 Non-covered Recipient Entity
Chesapeake Urology
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930651
Principal investigator 1 PFIZER INC. $30,805.26 12/28/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727913
Principal investigator 1 Janssen Research & Development, LLC $3,502.00 12/26/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382959
Principal investigator 1 MEDIVATION LLC. $1,002.45 12/24/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739410
Principal investigator 1 MEDIVATION LLC. $1,002.45 12/24/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739471
Principal investigator 1 Janssen Research & Development, LLC $152.00 12/12/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227868
Principal investigator 1 MEDIVATION LLC. $1,063.95 12/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720299
Principal investigator 1 MEDIVATION LLC. $1,002.45 12/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740387
Principal investigator 1 MEDIVATION LLC. $1,002.45 12/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740457
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,450.00 12/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892662
Principal investigator 1 Janssen Research & Development, LLC $304.00 12/01/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227586
Principal investigator 1 Janssen Research & Development, LLC $14,670.00 12/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382732
Principal investigator 1 AstraZeneca UK Limited $26,800.00 11/14/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES, PA
a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate No dispute reported 06/30/2026 1185555549
Principal investigator 1 PFIZER INC. $30,805.26 11/10/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727839
Principal investigator 1 PFIZER INC. $30,805.26 11/08/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727471
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,000.00 11/06/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892574
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,947.46 11/06/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Pa
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235998168
Principal investigator 1 MEDIVATION LLC. $1,002.45 11/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739648
Principal investigator 1 MEDIVATION LLC. $1,002.45 11/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740040
Principal investigator 1 MEDIVATION LLC. $1,002.45 11/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740645
Principal investigator 1 Janssen Research & Development, LLC $14,670.00 11/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382838
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,748.00 10/30/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225408916
Principal investigator 1 Celgene Corporation $36,000.00 10/23/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Pa
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1222305286
Principal investigator 1 PFIZER INC. $30,805.26 10/20/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726700
Principal investigator 1 PFIZER INC. $30,805.26 10/19/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727473
Principal investigator 1 Janssen Research & Development, LLC $7,004.00 10/06/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382790
Principal investigator 1 MEDIVATION LLC. $1,002.45 10/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739945
Principal investigator 1 MEDIVATION LLC. $1,002.45 10/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740601
Principal investigator 1 MEDIVATION LLC. $1,002.45 10/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740639
Principal investigator 1 PFIZER INC. $123,221.03 09/30/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727461
Principal investigator 1 PFIZER INC. $123,221.03 09/29/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727927
Principal investigator 1 Janssen Research & Development, LLC $4,271.00 09/26/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382884
Recipient PFIZER INC. $940.00 09/25/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727647
Principal investigator 1 Janssen Research & Development, LLC $235.20 09/22/2025 Non-covered Recipient Entity
Chesapeake Uro
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175230695
Principal investigator 1 Janssen Research & Development, LLC $78.64 09/19/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382822
Principal investigator 1 PFIZER INC. $46,207.89 09/10/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727547
Principal investigator 1 PFIZER INC. $46,207.89 09/09/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727941
Principal investigator 1 Janssen Research & Development, LLC $954.00 09/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382893
Principal investigator 1 Janssen Research & Development, LLC $304.00 09/05/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227533
Principal investigator 1 MEDIVATION LLC. $1,002.45 09/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742725
Principal investigator 1 MEDIVATION LLC. $1,002.45 09/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755764
Principal investigator 1 MEDIVATION LLC. $1,002.45 09/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756498
Recipient PFIZER INC. $3,200.00 08/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726598
Principal investigator 1 PFIZER INC. $46,207.89 08/21/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725582
Principal investigator 1 PFIZER INC. $46,207.89 08/20/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726698
Principal investigator 1 PFIZER INC. $30,805.26 08/11/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727765
Principal investigator 1 PFIZER INC. $30,805.26 08/10/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727939
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 08/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892356
Principal investigator 1 Dendreon Pharmaceuticals LLC $23,000.00 08/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892359
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,450.00 08/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892362
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,500.00 08/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892366
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 08/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892370
Principal investigator 1 Janssen Research & Development, LLC $500.00 08/01/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227693
Principal investigator 1 Janssen Research & Development, LLC $152.00 08/01/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227773
Principal investigator 1 MEDIVATION LLC. $1,002.45 08/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743321
Principal investigator 1 MEDIVATION LLC. $1,002.45 08/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755560
Principal investigator 1 Sumitomo Pharma America, Inc. $2,248.50 08/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641791
Principal investigator 1 Sumitomo Pharma America, Inc. $1,124.25 08/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641841
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,250.00 07/28/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies No dispute reported 06/30/2026 1225413026
Principal investigator 1 Janssen Research & Development, LLC $7,004.00 07/28/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382814
Principal investigator 1 PFIZER INC. $30,805.26 07/22/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727763
Principal investigator 1 PFIZER INC. $30,805.26 07/21/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724720
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $436.00 07/18/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402261
Principal investigator 1 PFIZER INC. $46,207.89 07/14/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726848
Recipient PFIZER INC. $330.00 07/11/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228722498
Principal investigator 1 PFIZER INC. $46,207.89 07/11/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727937
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 07/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640242
Principal investigator 1 Janssen Research & Development, LLC $152.00 07/04/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227781
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $19,613.00 07/03/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402263
Principal investigator 1 PFIZER INC. $77,013.15 07/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727915
Principal investigator 1 MEDIVATION LLC. $227.55 07/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743551
Principal investigator 1 MEDIVATION LLC. $1,002.45 07/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756186
Principal investigator 1 MEDIVATION LLC. $1,002.45 07/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756795
Principal investigator 1 PFIZER INC. $77,013.15 07/01/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725584
Principal investigator 1 Dendreon Pharmaceuticals LLC $22,001.50 06/30/2025 Non-covered Recipient Entity
ADVANCED UROLOGY PLLC
ProvONE No dispute reported 06/30/2026 1247892257
Principal investigator 1 Dendreon Pharmaceuticals LLC $125.00 06/30/2025 Non-covered Recipient Entity
ADVANCED UROLOGY PLLC
ProvONE No dispute reported 06/30/2026 1247892263
Principal investigator 1 PFIZER INC. $46,206.12 06/23/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753578
Principal investigator 1 PFIZER INC. $46,206.12 06/21/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753583
Principal investigator 1 PFIZER INC. $46,207.89 06/21/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755841
Principal investigator 1 Janssen Research & Development, LLC $78.64 06/16/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382853
Principal investigator 1 Janssen Research & Development, LLC $4,271.00 06/13/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382877
Principal investigator 1 Janssen Research & Development, LLC $823.20 06/12/2025 Non-covered Recipient Entity
Chesapeake Uro
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175230589
Principal investigator 1 Janssen Research & Development, LLC $7,004.00 06/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382967
Recipient Dendreon Pharmaceuticals LLC $19,000.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891677
Recipient Dendreon Pharmaceuticals LLC $6,500.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891680
Recipient Dendreon Pharmaceuticals LLC $211.99 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891684
Recipient Dendreon Pharmaceuticals LLC $16,000.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891689
Recipient Dendreon Pharmaceuticals LLC $6,500.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891692
Principal investigator 1 Dendreon Pharmaceuticals LLC $16,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247891953
Principal investigator 1 Dendreon Pharmaceuticals LLC $13,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247891957
Principal investigator 1 Dendreon Pharmaceuticals LLC $19,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892192
Principal investigator 1 Dendreon Pharmaceuticals LLC $13,000.00 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892197
Principal investigator 1 Dendreon Pharmaceuticals LLC $211.99 06/05/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC
ProvONE No dispute reported 06/30/2026 1247892201
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $21,102.00 06/02/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402265
Principal investigator 1 PFIZER INC. $46,206.12 06/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752636
Principal investigator 1 PFIZER INC. $46,206.12 06/01/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751647
Principal investigator 1 PFIZER INC. $46,207.89 06/01/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755161
Principal investigator 1 PFIZER INC. $30,804.08 05/27/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752040
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,862.90 05/26/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES, LLC
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190303317
Principal investigator 1 Janssen Research & Development, LLC $14,670.00 05/23/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382931
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719709
Principal investigator 1 MEDIVATION LLC. $484.62 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720529
Principal investigator 1 MEDIVATION LLC. $484.62 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724354
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724460
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778498
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789881
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789886
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789963
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790076
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790279
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790506
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790607
Principal investigator 1 MEDIVATION LLC. $484.62 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791013
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791149
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791158
Principal investigator 1 MEDIVATION LLC. $484.62 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791663
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792025
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792171
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792289
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792529
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792688
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792753
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792900
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792956
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792960
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793163
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793228
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793445
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793571
Principal investigator 1 MEDIVATION LLC. $484.62 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793653
Principal investigator 1 MEDIVATION LLC. $227.55 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793984
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228794035
Principal investigator 1 MEDIVATION LLC. $1,002.45 05/22/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228794039
Principal investigator 1 PFIZER INC. $30,804.08 05/22/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753883
Principal investigator 1 PFIZER INC. $30,805.26 05/22/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754886
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228723218
Principal investigator 1 Sumitomo Pharma America, Inc. $60.00 05/07/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634223
Principal investigator 1 PFIZER INC. $30,804.08 05/05/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753179
Principal investigator 1 PFIZER INC. $30,804.08 05/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753507
Principal investigator 1 PFIZER INC. $30,805.26 05/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754533
Principal investigator 1 Janssen Research & Development, LLC $152.00 04/30/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227849
Recipient PFIZER INC. $940.00 04/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769388
Principal investigator 1 Janssen Research & Development, LLC $14,670.00 04/21/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382996
Principal investigator 1 PFIZER INC. $123,216.32 04/14/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753758
Principal investigator 1 PFIZER INC. $123,216.32 04/12/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751744
Principal investigator 1 PFIZER INC. $123,221.04 04/12/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755126
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 04/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632679
Principal investigator 1 Sumitomo Pharma America, Inc. $6,281.00 04/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632693
Principal investigator 1 Sumitomo Pharma America, Inc. $3,427.00 04/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632720
Principal investigator 1 PFIZER INC. $46,206.12 04/03/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753880
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,882.00 04/02/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402429
Principal investigator 1 PFIZER INC. $46,206.12 04/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753502
Principal investigator 1 PFIZER INC. $46,207.89 04/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756239
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228779260
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228781318
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789905
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790136
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792907
Principal investigator 1 MEDIVATION LLC. $227.55 04/01/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793323
Principal investigator 1 Janssen Research & Development, LLC $954.00 03/31/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382975
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $436.00 03/28/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402431
Principal investigator 1 PFIZER INC. $46,206.12 03/14/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753754
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/13/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227739
Principal investigator 1 PFIZER INC. $46,206.12 03/13/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752036
Principal investigator 1 PFIZER INC. $46,207.89 03/13/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228757683
Principal investigator 1 Janssen Research & Development, LLC $150.00 03/07/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382915
Principal investigator 1 PFIZER INC. $30,804.08 03/04/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752953
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720465
Principal investigator 1 MEDIVATION LLC. $1,063.95 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720629
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722512
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724034
Principal investigator 1 MEDIVATION LLC. $227.55 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774310
Principal investigator 1 MEDIVATION LLC. $227.55 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774445
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774612
Principal investigator 1 MEDIVATION LLC. $227.55 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774649
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774871
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775037
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775096
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775454
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775611
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776042
Principal investigator 1 MEDIVATION LLC. $227.55 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776407
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776482
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777466
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777746
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777800
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778059
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228784621
Principal investigator 1 MEDIVATION LLC. $484.62 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228784653
Principal investigator 1 MEDIVATION LLC. $227.55 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785749
Principal investigator 1 MEDIVATION LLC. $1,002.45 03/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786098
Principal investigator 1 PFIZER INC. $30,804.08 03/03/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753174
Principal investigator 1 PFIZER INC. $30,805.26 03/03/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755209
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $536.00 02/25/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225404580
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,624.00 02/18/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402425
Principal investigator 1 Eli Lilly and Company $5,410.00 02/18/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187878087
Principal investigator 1 Janssen Research & Development, LLC $78.64 02/14/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382900
Principal investigator 1 Janssen Research & Development, LLC $10,236.00 02/10/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175382777
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $15,855.00 02/07/2025 Non-covered Recipient Entity
Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402427
Principal investigator 1 Eli Lilly and Company $24,885.87 02/06/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187878839
Principal investigator 1 Janssen Research & Development, LLC $954.00 02/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175382739
Principal investigator 1 Janssen Research & Development, LLC $681.00 02/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
Protocol 212082PCR2005 ?A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease No dispute reported 06/30/2026 1175382784
Principal investigator 1 PFIZER INC. $30,804.08 02/03/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753886
Recipient PFIZER INC. $940.00 02/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770949
Principal investigator 1 PFIZER INC. $30,804.08 02/01/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753750
Principal investigator 1 PFIZER INC. $30,805.26 02/01/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228759169
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/28/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777487
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $536.00 01/27/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225405238
Principal investigator 1 PFIZER INC. $46,206.12 01/23/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723982
Principal investigator 1 PFIZER INC. $46,206.12 01/22/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720321
Principal investigator 1 PFIZER INC. $46,207.89 01/22/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228758227
Principal investigator 1 PFIZER INC. $77,010.20 01/13/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753587
Principal investigator 1 PFIZER INC. $77,010.20 01/12/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751639
Principal investigator 1 PFIZER INC. $77,013.15 01/12/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755130
Principal investigator 1 Janssen Research & Development, LLC $152.00 01/10/2025 Non-covered Recipient Entity
Chesapeake Uro Associates, Pa
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175227842
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/09/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
Protocol 212082PCR2005 ?A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease No dispute reported 06/30/2026 1175382831
Principal investigator 1 AstraZeneca Pharmaceuticals LP $926,348.65 01/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES, PA
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185555551
Principal investigator 1 PFIZER INC. $46,206.12 01/06/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751642
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775068
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777951
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778075
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778250
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778373
Principal investigator 1 MEDIVATION LLC. $1,002.45 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786724
Principal investigator 1 PFIZER INC. $46,206.12 01/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722470
Principal investigator 1 PFIZER INC. $46,207.89 01/02/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755106

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $80,182.17 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $78,612.01 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $37,950.63 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $35,239.87 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $90,358.69 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $39,494.35 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $204.38 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771713
PY2024 SN Holdings, LLC $0.00 $79,977.79 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773461
PY2023 SN Holdings, LLC $0.00 $78,612.01 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887575
PY2022 SN Holdings, LLC $0.00 $37,950.63 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609541
PY2021 SN Holdings, LLC $0.00 $35,239.87 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125501
PY2020 UroGPO LLC $0.00 $90,358.69 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139319
PY2019 UroGPO LLC $0.00 $39,494.35 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690774895